002390.KS
HANDOK Inc.
KSC · Healthcare · Drug Manufacturers - Specialty & Generic · KR
KRW 9,520.00
−1.14%Year over year
Reported trailing growth
- Revenue
- +12.0%
- EBITDA
- +80.4%
- EBIT
- +223.3%
- EPS
- +90.3%
- Free cash flow
- —
- Operating cash flow
- -72.3%
Forward estimates
Based on analyst estimates
- Revenue
- -4.3%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -0.5%
- EBITDA
- -18.9%
- EBIT
- -44.7%
- Net income
- +95.9%
- EPS
- +95.7%
- Free cash flow
- +55.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026